Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 Corresponding patents have b...
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced that the European Unified Patent Court ("UPC") issued a...
Baird Medical's MWA products have been available in China for many years, and the Company is known as a market leader in MWA technology for thyroid and bre...
The aim of the LOVE-DEB Study (Large de-NOVo coronary artEry disease treated with sirolimus Drug Eluting Balloon: prospective evaluation of safety & ef...
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age a...
Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colo...
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prosta...
The study is a randomized, double-blind Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patie...
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1 Approval is based on interim data from ongoin...
To help protect access to medicines for cancer and rare disease patients, AstraZeneca has filed a legal challenge to critical aspects of the drug pri...
With a dual-headed probe, the Vscan Air SL offers a sector array and a linear array on a single device which is ideal for switching between focused cardi...
Boston Scientific Corporation (NYSE: BSX) announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed F...
PD-L1 IHC 22C3 pharmDx, Code SK006, is indicated as an aid in identifying certain cancer patients for treatment with KEYTRUDA® (pembrolizumab), Merck&r...
© 2023 Biopharma Boardroom. All Rights Reserved.
